



Montpellier, September 24, 2018 – 08:00am CEST

Intrasense and DMS Group put an end to exclusive negotiations

Intrasense (Euronext Growth - FR0011179886 - ALINS), specialist in medical imaging software solutions and designer of Myrian® and **DMS Group (Euronext - FR0012202497 - DGM)**, a high technology group serving medical diagnosis, healthcare and wellness, announce that their boards of Directors decided to put an end to discussions about the proposed contribution of the medical imaging division of DMS Group to Intrasense, started since the announcement of the project on May 15, 2018¹.

Discussions relating to the scope of the transferred activities and the terms of the combination did not lead to a satisfactory conclusion. Therefore, both companies have decided to end the negotiations under way.

Nevertheless, remaining convinced that an industrial partnership could be relevant for their mutual benefit, both companies should consider strengthening their commercial relations, in the coming months.

About Intrasense

Founded in 2004, Intrasense develops and markets a unique medical device called Myrian®, a software platform that facilitates diagnosis, decision-making and therapeutic follow-up and makes them more secure. Thanks to Myrian®, more than 800 health institutions spread over 40 countries use a unique and integrated platform supporting all types of imaging modalities (MRI, scanner...).

Enriched with expert clinical modules dedicated to specific pathologies, Myrian® also provides a universal image treatment solution that can be fully integrated in any health information system. Intrasense includes 45 employees among which 20 are dedicated to Research & Development. Intrasense has been labelled "innovative company" by the BPI and invested more than 10 million euros in Research & Development since its creation.

For more information, www.intrasense.fr.

Contacts

Intrasense
Nicolas Reymond
Chief Executive Officer
+334 67 130 130
investor@intrasense.fr

NewCap
Valentine Brouchet - Pierre Laurent
Investors Communication and Relations
+331 44 71 94 96
intrasense@newcap.eu

About DMS Group

DMS Group is composed of high potential of innovation companies. First concentrated on medical imaging industry, its activities have been extended to new horizons. Investing in the future by pledging research, DMS Group aims at providing tomorrow solutions.

¹ [Intrasense et DMS Group entrent en négociation exclusive en vue de l'apport des activités d'imagerie médicale de DMS Group à la société Intrasense](#)

- Specialist of high technology serving medical diagnosis, **DMS Imaging** is positioned today as a French leader of development, conception and design of imaging systems dedicated to radiology, osteodensitometry, 3D modelisation and posturology.
- **DMS Wellness** bundles the activities dedicated to healthcare and wellness sector, addressing specialists of physiotherapy, beauty, esthetics and sports.
- **DMS Biotech** supports the group strategy in biotechnologies, in particular in the treatment of arthrosis and regenerative medicine based on injection of stem cells from fat.

DMS Group is present on five continents through a national network of 140 distributors, subsidiaries and joint-ventures. In 2017, DMS Group generated consolidated turnover of €27.1 M.

For more information, www.dms.com.

Contacts

DMS Group
Jean-Paul ANSEL
Chief Executive Officer
+334 67 50 49 00

ACTUS FINANCE
Mathieu OMNES
Investors relations
+331 53 67 36 92

ACTUS FINANCE
Alexandra PRISA
Press relations
+331 53 67 36 90